Home » Newsletters » BioWorld Science

BioWorld Science

April 26, 2000

View Archived Issues

New agents for GI disorders patented by Byk Gulden

Inhibitors of PTP1B in early development at Merck

Proapoptotic and antiproliferative chroman-based compounds designed by RDF

Genentech makes progress on all fronts during first quarter

Polypeptides and their use for treating or diagnosing bacterial infections described by SB

Dual NOS inhibitors/antioxidants designed at SCRAS

Potential antiparkinsonian agents from Kyowa Hakko acting as adenosine A2A antagonists

CPI-1189 may provide neuroprotection via blockade of p38 MAPK phosphorylation

Japanese scientists synthesize new series of MMP inhibitors

Important European market introduction for RenaGel

Sankyo acquires expanded marketing rights to new antihyperlipidemic agent

Worldwide licensing agreement announced for MKC-733

Three products advance in Yamanouchi's clinical pipeline

Y-27632 demonstrates beneficial effects on hepatic fat-storing cells and hepatic fibrosis

Cortex and Shire enter agreement on CX-516 for treatment of ADHD

Genelabs discovers novel RNA-binding compounds

Cambridge Drug Discovery and Teijin to collaborate on novel lead compound development

Results of LeukArrest and Pafase clinical trials

EMEA issues warning and modified labeling for Viramune

Campath MAA accepted for review by European authorities

Discovery Therapeutics initiates phase II atrial fibrillation trial

Abbott and Chrysalis BioTechnology collaborate on Chrysalin development

Another mechanism of action of bacterial cell killing proposed for ramoplanin

Preliminary clinical data confirm positive effect of oral heparin dosage form

Bristol-Myers Squibb resubmits UFT NDA to FDA

New hope for patients suffering from Sjogren's syndrome: FDA approves cevimeline

Orion acquires worldwide rights to Nestorone as hormone replacement therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...